Torri Di Arcugnano

This research aims to collect data on the worldwide use and outcomes of Boston Scientific's Vercise Deep Brain Stimulation (DBS) System in treating Parkinson's disease. The study also evaluates the use of Image Guided Programming (IGP) and the DBS Illumina 3D feature as tools to assist in programming the DBS device for patients. Participants receiving DBS for Parkinson's symptoms will be included in this registry. The study observes how these programming features are applied in clinical settings to optimize treatment. There are no additional treatment groups or drug comparisons as this is a device registry. During the study, participants' symptom improvements and overall quality of life will be monitored and compared to their condition before DBS. The study follows patients for up to three years to assess long-term benefits and outcomes. Data collection includes evaluations of symptom changes and the effectiveness of programming tools used with the DBS system.